













### An established group




Turnover of € 344 million in 2013

## Sales 2000-2013 (million euros)



#### **Business units**



### Spain

- A Generics 77 %
- B QTCs 16 %
- C Dermo 1%

#### International

D - Generics + QTCs + Dermo 6%


#### **Product launches**



53%

We have a firm international commitment

Of the 118 new products launched in 2013 53% were destined for the international market.



We develop our products in Spain in compliance with the strictest quality standards of the European Medicines Agency (EMEA), offering solutions in 50 countries all around the world.

We adapt to each market, country and person, adjusting our portfolio and presentations to the needs of the countries where we operate, complying with each country's requirements.

in 50 countries in the world

#### 2011-2013 investment 40,3 million in production capacity euros







#### Be+ Cell Energy Booster® Cinfa innovation

Be+ Cell Energy Booster is an exclusive active developed by Be+ based on protein microcapsulation. This active ingredient increases in 40% skin's cell's energy, significantly improving the effectiveness of our anti-aging treatments.



# R&D&i

/ In 2013, we have successfully completed the development of 27 products / / We cooperate with

more than 80 universities and international research centers / Our Scientific Area currently manages more than 75 projects in different stages of development /

## Committed to innovation

At Cinfa we offer our clients a wide portfolio of generic drugs, as well as over-the-counter (OTC) products with a real, differential and innovative value

This commitment is backed by research and innovation, with an investment of €47 million in the last three years and planned investments of €74 million for 2014, 2016

## We continue moving forward

In the field of skin care, Be+ is working in new micro-capsulated active ingredients focused on restoring required energy levels for skin cells to perform their functions optimally.

Moreover, in the nutrition field Cinfa has come with the development of new nutrition solutions (N<sup>SO</sup>) and cutting edge research on future nutraceutics with patented active ingredients. All those initiatives require Cinfa's R+D+I team to work in collaboration with different companies, technology centers, foundations and universities.

## Highly Specialised Generic Drugs

Product launches such as Anastrozole and Letrozole are clear examples of our capacity to develop highly specialised generic drugs.

Another of our outstanding developments is Tacrolimus, approved for marketing in 26 countries in Europe.





#### Cinfa's Scientific Area

Cinfa's Scientific Area comprises 58 doctors, graduates and technical experts in Pharmacy, Chemistry, Medicine and Biology.

It is currently managing more than 75 projects in different stages of development, working in cooperation with 80 universities and research centres in Europe, America and Asia.



# Generic Drugs



Production plant for Highly-Specialised Generic Drugs / We are leaders in the Spanish generic\* drug market /
/ We are present in all therapeutic areas
with more than 400 presentations /
/ All our products are bioequivalent /

**Extensive** 

in 1998.

**Experience** 

\* In terms of volume. Source: IMS 2013

# Highly Specialised Generic Drugs

Cinfa has a specific production plant for Highly Specialised Generic Drugs.

Highly Specialised Generic Drugs are used in specific therapeutic areas such as oncology and transplants.

Technically, their pharmaceutical and clinical development is highly complex and special measures need to be taken during the manufacturing processes of these drugs.

#### A commercial success

Atorvastatine Cinfa is one of Cinfa's comercial successes accounting for 10% of total turnover for generics.









650 million units of generic drugs manufactured since our first launch

#### **Branded Generics**

In 2013, Cinfa launched its first branded generics in the Persian Gulf region, one of our main commitments in international markets.

# Bioequivalent products

All of our generic drugs are bioequivalent guaranteeing that our treatments are as effective as the reference products.


To ensure their quality, all generics have to pass strict tests that clinically verify their bioequivalence. These are performed at external research centres authorised by the European Medicines Agency (EMA).

#### Bioequivalents to the reference product in each market

At Cinfa we adapt to each market. This is why our generic drug developments, are adapted not only to branded products, but also have the specific properties of the reference product in the specific market.



/ We are present in all therapeutic areas with more than 400 presentations /





#### Pharmagrip Dúo

We have a wide range of products for consumer healthcare. Pharmagrip Dúo is a leader in the area of anti-flu formulations. Its innovative product form, which requires no water, makes it an ideal solution that adapts to users' pace of life.




#### Nutrition and health solutions Ns®

- · Cardiovascular health.

# Consumer health

/ We are Spain's first-largest manufacturer of over-the-counter products (OTC)\* / / N<sup>S®</sup> Nature System: prevention through nutrition /

\* Source: IMS 2013





## Adapted to each market

We always think about our target markets when we develop our products, adapting presentations and packaging, and complying with their specific pharmaceutical regulations.

#### Therapeutic areas

Our OTC portfolio covers a wide spectrum of therapeutic areas: antihistaminics, analgesics,




### **Sports activities**

Cinfa's orthopaedic products have been developed to aid the practice of sports. We offer you a wide range of thermal neoprene products, with modern, sporty designs for perfect grip whatever your sport.

# Farmalastic

/ We are leaders in Spain with a 43,1% market share\* /

\* Source: IMS 2013



# Innovation and design for healthy feet

A significant proportion of the population suffers from some kind of foot pain. That's why we offer a wide range of podiatry products that provide you with high quality protection.

## A wide range of products

Our Farmalastic brand of orthopaedic products has been developed to prevent and treat venous and skeletal-muscle conditions.

Stockings, joint supports (for wrists, knees and elbows, slings, neck supports, thermal neck, heat-cold packs), corsets, thermal neoprene, clogs (relax, comfort, micro-massage), bandages.





Be + Cell Protection Complex® is an innovative biotechnologically produced active ingredient that protects the

Be+

# Photoprotection Be+ Cell Protection Complex®

All our solar treatments: UVA and UVB protection Water resistant For sensitive skins Hypoallergenic Dermatologically tested Paraben free Allergen-free perfumes

/ Cinfa focuses its research on Cellular Energy /
/ Exceptional textures even for the most sensitive skins /
/ Treatments adapted to each consumer's needs /

#### Be+ Cell Energy Booster, your skin's cellular energy

The scientific team behind Be+ by Cinfa has conducted research studies and developed new, innovative substances, patent pending, based on the cell senescence concept.

Be+ cell Energy Booster is an innovative ingredient who gives the cells back their capacity of producing the energy they loose with time and increase it by 40%.

Only then your skin will be healthy and ready to make the maximum of Be+ anti-aging treatments, since cosmetic actives do not achieve the same results over a powerless cell.





Cinfa's Be+, skincare brand comprises 55 products in 14 ranges.

#### Our treatments are:

- Tested on sensitive and reactive skins
- Dermatologically tested
- Paraben free
- Allergenic fragrance free
- Fragrance free eye contour in order to minimize eye discomfort risk



Be+

DÍA & NOCHE

Be+









# Licensing out

/ We have a wide variety of molecules in different stages of development / / A service fully-customised to our clients' needs / / We have innovative production plants /

# A service fully-customised to our clients' needs

We offer a comprehensive service, adapted to our clients, providing them with the most modern, innovative production capacities for oral, solid and liquid forms.

We manage all stages of a product, from development and market registration through manufacturing.

Based on our experience, quality and flexibility, other important pharmaceutical companies trust us to develop generic drugs, which they market under their own brands.

#### **European Quality**

All our products comply with European Medicines Agency regulations (EMA).

This means we guarantee high quality European drugs developed for any market in the world.

Currently, we are also working to certificate Cinfa with the FDA standards.





